Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.

ABSTRACT:

Introduction

There is broad consensus that high grade basal proteinuria and failure to achieve remission of proteinuria are key determinants of adverse renal prognosis in patients with primary membranous nephropathy. Based on the fact that current regimens are not ideal due to short and long-term toxicity and propensity to relapse after treatment withdrawal, we developed a treatment protocol based on a novel combination of rituximab and cyclosporine which targets both the B and T cell limbs of the immune system. Herein, we report pilot study data on proteinuria, changes in autoantibody levels and renal function that offer a potentially effective new approach to treatment of severe membranous nephropathy.

Methods

Thirteen high-risk patients defined by sustained high-grade pro

SUBMITTER: Waldman M 

PROVIDER: S-EPMC5138549 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature